JNCCN-360

Site Editor: David S. Ettinger, MD

Advertisement

Advertisement

Results From the ARCHER 1050 Trial

Results From the AvaALL Trial

The What, When, and How of Biomarker Testing

Recent

Investigational First-Line Combination Treatment for EGFR-Mutant Lung Cancers

Ado-trastuzumab Emtansine in HER2-Overexpressing Metastatic NSCLC

Priority Review Granted for Alectinib for Initial Treatment of ALK-Positive Lung Cancer

Durvalumab Granted Breakthrough Therapy Designation in Locally Advanced Lung Cancer

In the

Medical Literature

Driver Mutations and Therapy Selection for Lung Adenocarcinoma

Concurrent Chemotherapy and Proton Therapy in Advanced Lung Cancer

Robot-Assisted Thoracic Surgery for Lung Lobectomy in NSCLC

Brigatinib in Crizotinib-Refractory ALK-Positive Non–Small Cell Lung Cancer

Active

Treatment of EGFR-Mutated NSCLC: Assessing Your Clinical Practice

Case Studies in ALK-Translocated Advanced NSCLC: From Diagnosis to Treatment

ASTRO Issues New Guidelines on Stereotactic Radiation in Early NSCLC

A Patient-centric, Performance Measures-based Approach to NSCLC

Available

Clinical Trials

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

The University of Texas MD Anderson Cancer Center

Fox Chase Cancer Center

University of Alabama at Birmingham Comprehensive Cancer Center

Sections

NCCN Resources

Copyright © 2017 National Comprehensive Cancer Network, All Rights Reserved